<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633889</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003605</org_study_id>
    <secondary_id>R01DK125786</secondary_id>
    <nct_id>NCT04633889</nct_id>
  </id_info>
  <brief_title>Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury</brief_title>
  <acronym>DEFEAT-AKI</acronym>
  <official_title>Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple lines of evidence support a central role of iron in causing acute kidney injury&#xD;
      (AKI), including the finding that prophylactic administration of iron chelators attenuates&#xD;
      AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to&#xD;
      iron-mediated kidney injury due to the profound hemolysis that often occurs from&#xD;
      cardiopulmonary bypass. The investigators will test in a phase 2, randomized, double-blind,&#xD;
      placebo-controlled trial whether prophylactic administration of deferoxamine decreases the&#xD;
      incidence of AKI following cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>7 days</time_frame>
    <description>Composite outcome that includes any of the following:&#xD;
Urine output &lt;0.5 ml/kg/h for ≥6 consecutive hours within the first 48h or until the Foley catheter is removed, whichever occurs first&#xD;
Increase in serum creatinine ≥0.3 mg/dl within the first 48h&#xD;
Increase in serum creatinine ≥50% within 7 days&#xD;
Receipt of renal replacement therapy within 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal tubular injury</measure>
    <time_frame>3 days</time_frame>
    <description>Urine levels of NGAL and KIM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Kidney Events</measure>
    <time_frame>7 days</time_frame>
    <description>Increase in serum creatinine ≥100%, receipt of renal replacement therapy, or death within 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative myocardial injury</measure>
    <time_frame>2 days</time_frame>
    <description>Peak postoperative troponin I elevation &gt;10 times the 99th percentile upper reference limit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation or atrial flutter</measure>
    <time_frame>7 days</time_frame>
    <description>New onset postoperative atrial fibrillation or atrial flutter (patients with atrial fibrillation or atrial flutter at baseline will be excluded)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged mechanical ventilation</measure>
    <time_frame>24 hours</time_frame>
    <description>Requirement for mechanical ventilation &gt;24h postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive-Inotropic Score</measure>
    <time_frame>24 hours</time_frame>
    <description>Validated method for integrating all IV vasoactive medications and their doses on an hourly basis into a single measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to liberation from vasoactive medications</measure>
    <time_frame>7 days</time_frame>
    <description>Number of hours from time of incision to liberation from all IV vasoactive medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis</measure>
    <time_frame>7 days</time_frame>
    <description>Life-threatening organ dysfunction caused by a dysregulated host response to infection. Organ dysfunction is defined as an acute increase in the total SOFA score ≥2 points consequent to the infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days</time_frame>
    <description>28 minus the number of days ventilated. Patients who die within 28 days will be assigned 0 ventilator-free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>28 days</time_frame>
    <description>28 minus the number of days in the ICU. Patients who die within 28 days will be assigned 0 ICU-free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days</measure>
    <time_frame>28 days</time_frame>
    <description>28 minus the number of days hospitalized. Patients who die within 28 days will be assigned 0 hospital-free days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Deferoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (240mL) intravenous infusion over 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferoxamine</intervention_name>
    <description>Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours</description>
    <arm_group_label>Deferoxamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline (240mL) intravenous infusion over 12 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Undergoing coronary artery bypass graft and/or valve surgery with cardiopulmonary&#xD;
             bypass&#xD;
&#xD;
          3. AKI risk score ≥6 at the time of screening&#xD;
&#xD;
          4. Written informed consent from the patient or surrogate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AKI, defined as any of the following:&#xD;
&#xD;
               -  Increase in serum creatinine ≥0.3 mg/dl in 48h&#xD;
&#xD;
               -  Increase in serum creatinine ≥50% in 7d (if no value available in last 7d, use&#xD;
                  most recent value in last 3 months)&#xD;
&#xD;
               -  Urine output ≤0.5 ml/kg/h x 6 consecutive hours (only assessed in patients with&#xD;
                  hourly monitoring via Foley catheter)&#xD;
&#xD;
               -  Receipt of renal replacement therapy (RRT) within 7d&#xD;
&#xD;
          2. Advanced chronic kidney disease (eGFR &lt;15 ml/min/1.73m2 or end-stage kidney disease&#xD;
             receiving RRT)&#xD;
&#xD;
          3. Hemoglobin &lt;8 g/dL (closest value in the prior 3 months)&#xD;
&#xD;
          4. Fever (temperature ≥38⁰C) in the last 48h&#xD;
&#xD;
          5. Suspected or confirmed bacteremia, endocarditis, or pyelonephritis&#xD;
&#xD;
          6. Pneumonia, aspiration, or bilateral pulmonary infiltrates from an infectious etiology&#xD;
             reported on chest x-ray or CT scan in the last 7d&#xD;
&#xD;
          7. Positive COVID-19 test within previous 3 weeks&#xD;
&#xD;
          8. Chronic iron overload (including conditions such as hemochromatosis and beta&#xD;
             thalassemia major) or previous iron chelation therapy (including prior participation&#xD;
             in DEFEAT-AKI)&#xD;
&#xD;
          9. Known hypersensitivity to deferoxamine&#xD;
&#xD;
         10. Taking prochlorperazine&#xD;
&#xD;
         11. Severe hearing loss&#xD;
&#xD;
         12. Pregnant or breastfeeding&#xD;
&#xD;
         13. Prisoner&#xD;
&#xD;
         14. Concurrent participation in another interventional research study in which the&#xD;
             intervention has potential interaction with deferoxamine&#xD;
&#xD;
         15. Surgery to be performed under conditions of circulatory arrest&#xD;
&#xD;
         16. Receiving extracorporeal membrane oxygenation&#xD;
&#xD;
         17. Durable ventricular assist device (VAD) prior to surgery (does not include Impella&#xD;
             device or intra-aortic balloon pump)&#xD;
&#xD;
         18. Any condition which, in the judgement of the investigator, might increase the risk to&#xD;
             the patient&#xD;
&#xD;
         19. Conflict with other research studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E. Leaf, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David E. Leaf, MD, MMSc</last_name>
    <phone>9144190622</phone>
    <email>deleaf@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shahzad Shaefi, MD, MPH</last_name>
    <phone>6178203570</phone>
    <email>sshaefi@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aranya Bagchi, MBBS</last_name>
      <email>abagchi@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David E. Leaf, MD, MMSc</last_name>
      <phone>914-419-0622</phone>
      <email>deleaf@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahzad Shaefi, MD, MPH</last_name>
      <email>sshaefi@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sharma S, Leaf DE. Iron Chelation as a Potential Therapeutic Strategy for AKI Prevention. J Am Soc Nephrol. 2019 Nov;30(11):2060-2071. doi: 10.1681/ASN.2019060595. Epub 2019 Sep 25. Review.</citation>
    <PMID>31554656</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>David Leaf</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

